Research will focus on interplay between HIV Env structure and function
Dr. M. Gordon Joyce joined MHRP earlier this month as Chief of the newly created Structural Biology lab section.
Structure-based HIV vaccine design allows for the development of novel immunogens that can target the induction and development of specific antibodies targeted to neutralization-sensitive sites on the HIV virus. The Joyce lab will the interplay between HIV Env structure and function including Env sequence diversity, glycan shielding and structural malleability and how this information can be used to develop novel Env-based immunogens capable of eliciting broadly protective antibodies.
Dr. Joyce received a B.Sc. in Biochemistry from the National University of Ireland, Galway in 2001, followed by a Ph.D. in Structural Biology from the University of Leicester in 2006. He then began work on the structural characterization of human immunoreceptors with Dr. Peter Sun in the Laboratory of Immunogenetics at NIH.
In 2011, he moved to the NIH’s Vaccine Research Center working with Dr. Gary Nabel, Dr. Peter Kwong and Dr. John Mascola on the structure-based design of HIV-1, Influenza and RSV vaccine candidates. Most recently, he has been involved in the study of understanding the induction and prevalence of broadly protective antibodies in humans following infection or vaccination.
Dr. Joyce is an author of over 50 peer-reviewed manuscripts and a co-inventor on 7 patents describing vaccine immunogens and monoclonal antibody therapeutics for HIV-1, Influenza, RSV, and MERS.